NEC OncoImmunity AS

Visit Tool

NEC OncoImmunity AS provides AI-driven machine-learning software for predicting immunogenic antigens. It focuses on personalized cancer immunotherapy and infectious disease vaccines, aiding in patient selection and neoantigen identification.

Claim this tool

No Views Yet

At a glance

Pricing

—

Free tier

—

API

—

Skill level

Technical

About

What is NEC OncoImmunity AS?

NEC OncoImmunity AS is a biotech company leveraging artificial intelligence to develop machine-learning software. This software is designed to predict immunogenic antigens, playing a crucial role in the fields of personalized cancer immunotherapy and infectious disease vaccines. Key applications include facilitating patient selection for cancer immunotherapy treatments and identifying specific neoantigen targets for the development of personalized cancer vaccines and cell therapies. The company's technology aims to advance precision medicine in oncology and infectious disease prevention.

Best used for

Predicting immunogenic antigens to advance personalized cancer immunotherapy and infectious disease vaccine development.

Common actions

Predict immunogenic antigens

Develop cancer vaccines

Personalize cancer therapy

Identify neoantigens

Research infectious diseases

Capabilities

Key features

AI-driven antigen prediction
Personalized cancer immunotherapy
Infectious disease vaccines
Patient selection
Neoantigen identification

Target Audience

Biotech companiesPharmaceutical researchersOncologistsImmunologists

Integrations

Not yet documented

Pricing & Plans

unknown

Not publicly disclosed. Check nec-bio.com for current pricing.

FAQs

What types of data are required for the AI-driven antigen prediction, and how is patient privacy handled?

NEC OncoImmunity's platform typically utilizes genomic and transcriptomic data (e.g., tumor and normal tissue sequencing) for neoantigen prediction. Specific details on data input formats and patient privacy protocols, including compliance with regulations like GDPR and HIPAA, would be outlined in partnership agreements and data processing addendums.

How does NEC OncoImmunity AS validate the immunogenicity predictions made by its AI software?

The company validates its predictions through a combination of in silico methods, in vitro assays (e.g., T-cell activation assays), and in vivo studies, often in collaboration with academic institutions and pharmaceutical partners. Clinical trial data from ongoing immunotherapy programs also serve to validate the predictive power of their algorithms.

What is the typical turnaround time for neoantigen identification and patient selection analysis using this platform?

The turnaround time can vary significantly based on the scope of the project, the volume of samples, and the specific analysis required. For research collaborations or clinical trial support, timelines are usually established through direct consultation and depend on the integration with existing laboratory workflows and data processing pipelines.

Trending

Subcategories trending in Wellness & Lifestyle

Clinical & Healthcare Pro Health & Fitness Gaming & Entertainment Mental Wellness Self-Improvement Medical & Symptom Checking

Trending

Explore

Browse AI tools by category

Content & Design Productivity & Business Coding & Development AI Agents & Automation Research & Education Wellness & Lifestyle Career Development Marketing & Growth Data & Analytics Customer Support & CX Finance E-commerce